


Intellectual Property

Tissue Genesis, Inc. is an emerging high-growth company in the field of regenerative medicine, using a patient's own cells to coat implants, repair damaged tissue, heal disease, and address other medical concerns. Tissue Genesis is leveraging its perfusion platform and expertise to deliver products to the regenerative medicine market. Current near term applications include coating of implantable devices such as vascular grafts and stents; repair of tissue damaged by heart disease and peripheral artery disease; orthopedic and veterinary applications; and other tissue healing using a patient's own regenerative cells.



In Tissue Genesis' patented process, a small amount (about 60cc) of a patient's adipose (fat) tissue is needle-liposuctioned and processed into a pellet of therapeutic cells, including microvascular endothelial cells, adult stem cells, and other regenerative cells. These cells can be delivered back to the patient in a coated vascular graft or stent, or directly injected into damaged tissue, such as damaged heart tissue.


Patents

Exclusive licensee of the pioneering adipose derived stromal cell patent portfolio of Dr. Stuart Williams from Thomas Jefferson University:

- US 4,820,626 Method of Treating a Synthetic or Naturally Occurring Surface with Microvascular Endothelial Cells, and the Treated Surface Itself
- US 4,883,755 Method of Reendothelializing Vascular Linings
- US 5,035,708 Endothelial Cell Procurement and Deposition Kit
- US 5,131,907 Method of Treating a Synthetic or Naturally Occurring Surface with a Collagen Laminate to Support Microvascular Endothelial Cell Growth, and the Surface Itself
- US 5,230,693 Implantable Prosthetic Device for implantation into a Human Patient Having a Surface Treated with Microvascular Endothelial Cells
- US 5,312,380 Endothelial Cell Procurement and Deposition Kit
- US 5,372,945 Device and Method for Collecting and Processing Fat Tissue and Procuring Microvascular Endothelial Cells to Produce Endothelial Cell Product
- US 5,441,539 Endothelial Cell Deposition Device
- US 5,628,781 Implant Materials, and Methods of Treating the Surface of Implants with Microvascular Endothelial Cells, and the Treated Implants Themselves

Tissue Genesis:

- US 7,270,996 Automated Bioculture and Bioculture Experiments System



Patent Applications

Exclusive license from the University of Arizona: *A Method of Prevascularizing a Biomaterial Vascular Mimic for Drug and Device Evaluation Calcium Phosphate Surfaces to Support Adipose Tissue Derived Cell Proliferation and Differentiation*

Exclusive license from Dr. Keith March, MD, PhD: *Adipose Stromal Stem Cells for Tissue and Vascular Modification*

Tissue Genesis: *Prevascularized Devices and Related Methods Catheter for Cell Delivery Cell Seeding Method and Apparatus Cell Separation Apparatus and Methods of Use Cell Delivery Matrices Apparatus and Methods for Preparing Tissue Grafts*

Trademarks

United States and international trademark applications pending for Adipase, Tissue Genesis, and Tissue Genesis wave logo



tissue genesis incorporated

677 Ala Moana Boulevard, Suite 1100, Honolulu, Hawaii 96813
808.539.9331 / www.tissuegenesis.com

Copyright 2009 Tissue Genesis, Inc. All rights reserved. "Tissue Genesis," "TGI," the Tissue Genesis wave logo, and Tissue Genesis' product names, including "Cell Isolation System" and "Adipase," are trademarks of Tissue Genesis. The product images and descriptions contained herein are for informational purposes only. The described products have not been approved by the US FDA for any application. The information contained herein is subject to change without notice. Tissue Genesis shall not be liable for errors contained herein or consequential damages in connection with furnishing, performance, or use hereof. This brochure includes statements which may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Although Tissue Genesis believes the expectations contained in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. This information may involve risk and uncertainties that could cause actual results to differ materially from the forward-looking statements. [v20.01.06.18.09]